Welcome to our dedicated page for Fulcrum Therapeutics news (Ticker: FULC), a resource for investors and traders seeking the latest updates and insights on Fulcrum Therapeutics stock.
Fulcrum Therapeutics, Inc. reports developments as a clinical-stage biopharmaceutical company developing small-molecule therapies for genetically defined rare diseases and rare hematological disorders. Its lead clinical program, pociredir, is designed to increase fetal hemoglobin for the treatment of sickle cell disease, and company updates commonly address PIONEER trial data, markers of hemolysis and anemia, and sickle cell disease collaborations.
FULC news also covers quarterly financial results, corporate presentations, Nasdaq inducement equity grants, board composition, and updates to the company's pipeline and financial position as it advances small molecules that modulate gene expression.
Fulcrum Therapeutics (Nasdaq: FULC) granted inducement stock options to two new employees under its 2022 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
The company granted a total of 55,500 options on an effective date of May 4, 2026 at an exercise price of $7.02 per share. Options have a 10-year term and vest over four years: 25% on the first anniversary, then 6.25% each quarter for the following 12 quarters, subject to continued service.
Fulcrum Therapeutics (Nasdaq: FULC) reported Q1 2026 results and business highlights on April 27, 2026. Key items: positive Phase 1b pociredir data showing robust, rapid HbF induction and improved hemolysis/anemia markers; plan to pursue a potential registration‑enabling trial in H2 2026 pending FDA feedback; dosed first patient in a long‑term open‑label trial; appointed Dr. Josh Lehrer to the board; CFO Alan Musso plans to retire later in 2026. Cash, cash equivalents, and marketable securities were $333.3 million as of March 31, 2026, with an expected cash runway into 2029.
Fulcrum Therapeutics (NASDAQ: FULC) appointed Josh Lehrer, M.D., M.Phil., FACC to its Board of Directors as an independent director effective April 27, 2026. Dr. Lehrer is a physician-scientist and biotech executive with over two decades of clinical development experience.
He currently serves as CEO of Marea Therapeutics and previously was CEO of Graphite Bio (Apr 2020–Sep 2023) and CMO at Global Blood Therapeutics, where he oversaw development and approval of Oxbryta (voxelotor). Fulcrum said his experience will support advancement of pociredir and its benign hematology pipeline.
Fulcrum Therapeutics (Nasdaq: FULC) will release its first quarter 2026 financial results on Monday, April 27, 2026, before U.S. markets open. Management will host a conference call and webcast at 8:00 a.m. ET to discuss results and recent corporate developments.
Investors may register to receive dial-in details and a unique PIN; an audio webcast and archived replay will be available via the Investor Relations site at www.fulcrumtx.com.
Fulcrum Therapeutics (NASDAQ: FULC), MedicAlert Foundation, and Sickle Cell Disease Association of America announced a three-year partnership on March 19, 2026 to speed emergency department care for people with sickle cell disease by providing MedicAlert Smart Medical ID Cards linked to physician-approved digital care plans.
The program enables ED clinicians to scan a card QR code to access pain plans, hematologist contacts, medications, allergies, and other critical health information to reduce delays during pain crises.
Fulcrum Therapeutics (Nasdaq: FULC) granted non‑statutory stock options to one new employee as an inducement under Nasdaq Listing Rule 5635(c)(4). The company awarded 34,000 options at an exercise price of $7.81 per share (closing price on March 2, 2026).
The options carry a 10‑year term and vest over four years: 25% on the first anniversary of employment, then 6.25% quarterly over the following 12 quarters, subject to continued service. The award was made pursuant to the company’s 2022 Inducement Stock Incentive Plan.
Fulcrum Therapeutics (Nasdaq: FULC) will present at the Leerink Partners Global Healthcare Conference in Miami on Tuesday, March 10, 2025 at 1:00 p.m. ET.
The presentation will be webcast and accessible via the company’s Events and Presentations investor web page, with a replay available for at least 30 days after the event.
Fulcrum Therapeutics (Nasdaq: FULC) reported positive 12-week Phase 1b PIONEER data for pociredir in sickle cell disease, with mean absolute fetal hemoglobin (HbF) rising 12.2% from 7.1% to 19.3% at Week 12 and improvements in hemolysis, anemia markers, and VOC trends.
The company ended 2025 with $352.3 million cash and plans a potential registration-enabling trial in H2 2026, expecting cash runway into 2029.
Fulcrum Therapeutics (Nasdaq: FULC) reported positive 12-week results from the 20 mg cohort of the Phase 1b PIONEER trial of pociredir in sickle cell disease. Mean absolute fetal hemoglobin (HbF) rose by 12.2% to 19.3%, F-cells increased from 31% to 63%, mean hemoglobin rose by 1.1 g/dL, and markers of hemolysis improved. Seven of 12 patients achieved HbF ≥20% and seven reported zero VOCs during treatment. Pociredir was generally well-tolerated with no treatment-related SAEs. Fulcrum plans a potential registration-enabling trial in H2 2026 and will discuss next-step design with regulators.
Fulcrum Therapeutics (Nasdaq: FULC) will present 12-week results from the 20 mg dose cohort of the Phase 1b PIONEER trial of pociredir in sickle cell disease on Tuesday, February 24, 2026 at 8:00 a.m. ET.
Management and Dr. Martin Steinberg will discuss the data via live webcast; registration is available on the company’s Events and Presentations page and a replay will be posted after the event.